info@flamel.com
Home | Company | Technologies and Products | Investor Relations | Press Releases | Contact
 
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
Archives


Latest News

March 8, 2010
Flamel Technologies Announces Fourth Quarter and Year-End 2009 Results


A conference call to discuss the earnings is scheduled for 8:30 AM EST on March 09, 2010.
The dial-in number (for investors in the U.S. and Canada) is 1-877-857-6173; the conference ID number is 2453008.
International investors are invited to dial 1 719-325-4888.
 Webcast

March 1, 2010
Flamel Technologies Announces Projected Release Date of Fourth Quarter and Annual Results; Conference Call

December 18, 2009
Flamel Technologies Announces the Initiation of a Phase 2a Clinical Trial of Flamel's IFN-Alpha-2b XL in Patients with Chronic Hepatitis C Virus Infection

November 16, 2009
Flamel Technologies Announces Third Quarter 2009 Results; Additional New Projects; Cash Increases from $45.1 to $48.8 million
A conference call to discuss earnings is scheduled for 8:30 AM EST November 16, 2009.
The dial-in number (for investors in the U.S. and Canada) is 1-800-860-2442; the conference ID number is 435349.
International investors are invited to dial 1 412-858-4600.
 Webcast

November 04, 2009
Flamel Technologies Announces Licensing Agreement with Pfizer

September 18, 2009
Flamel Technologies to Present at UBS Global Life Sciences Conference

Medusa®

A Versatile Nano Carrier for the Delivery of Native Proteins

Medusa®, a self-assembled poly-aminoacid nanoparticles system, is a versatile protein carrier for the development of novel and second-generation long-acting native protein drugs. more info
Micropump® Technologies
From Pediatric to Geriatric Uses

Controlled-release systems permitting either extended (Micropump® I) or both delayed and extended (Micropump® II) delivery of small molecule drugs.

more info


December 21, 2004
Flamel Technologies Announces Completion of a Commercial Supply Agreement with Glaxo-Smith Kline for Drug in Phase III Trials

December 17, 2004
Flamel Technologies Announces Initiation of Phase I/II trial of Medusa Formulation of Long-Acting Interferon-alpha for Hepatitis B and Hepatitis C Treatment

December 8, 2004
Flamel Technologies Announces Initiation of Phase I/II trial of Medusa Formulation of Long-Acting Interleukin-2 for Cancer Treatment

October 28, 2004
Flamel Technologies Announces Third Quarter Results
Transcript of the conference call

October 25, 2004
Flamel Technologies Announces Projected Release Date of Third Quarter, Conference Call

September 16, 2004
Flamel Technologies Announces the License of Flamel's Micropump Technology to TAP Pharmaceutical Products Inc. for Lansoprazole, Conference Call
Webcast

September 16, 2004
Flamel Technologies Announces Initiation of Phase III trial for Micropump Formulation of a GlaxoSmithKline Product, Conference Call
Webcast

September 16, 2004
Flamel Technologies Announces Termination of License Agreement for Long-Acting Insulin, Conference Call
Webcast

July 29, 2004
Flamel Technologies Announces Second Quarter Revenues of $9.0 Million, Cash at $101 Million
Webcast for Q2 2004
Replay of the CC: (800) 642-1687 (US) or (706) 645-9291 (international)
conference ID: 8771969
Transcript of the conference call

July 26, 2004
Flamel Technologies Announces Projected Release Date of Second Quarter Results, Conference Call

July 1, 2004
Flamel Technologies Announces Selection of a Flamel Micropump Formulation to Progress to Phase III Clinical Trials

April 29, 2004
Flamel Technologies Announces First Quarter Revenues of $14.4 Million, Earnings of $0.20 Per Share

April 26, 2004
Flamel Technologies Announces Projected Release Date of First Quarter Results, Conference Call

April 1, 2004
Flamel Technologies announces receipt of $5 million milestone payment from Bristol-Myers Squibb Company

March 11, 2004
Flamel Technologies announces fourth quarter and year end 2003 results

March 4, 2004
Flamel Technologies announces projected release date of fourth quarter and year end results, conference call

January 5, 2004
Flamel Technologies announces receipt of milestone payment from GlaxoSmithKline

Micropump® and Medusa® are registered trademarks of Flamel Technologies S.A.
Copyrights © 2006 Flamel Technologies S.A. All rights reserved